FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to recovered monoclonal antibodies, particularly CDR-grafted humanised antibodies binding to an epitope of human RAGE molecule, and particularly possess an ability to inhibit RAGE binding to various ligands. The invention also refers to a method for preparing the above antibodies, a recovered nucleic acid coding them, an expression vector, a host cell and a pharmaceutical composition.
EFFECT: invention provides treating the diseases or disorders associated with advanced glycation end product (RAGE) receptor, including Alzheimer's disease effectively.
16 cl, 13 dwg, 10 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES | 2006 |
|
RU2442793C2 |
| MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
| MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF | 2006 |
|
RU2432362C2 |
| TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
| IMMUNOGENIC PRODUCTS OBTAINED BASED ON AMINO ACID SEQUENCES OF MUTEIN AMYLOID β (Aβ) AND THEIR APPLICATION METHODS | 2015 |
|
RU2750268C2 |
| POLYPEPTIDES FOR BONDING WITH "RECEPTOR OF ADVANCED GLYCATION ENDPRODUCTS", THEIR COMPOSITIONS AND METHODS, WHICH THEY TAKE PART IN | 2010 |
|
RU2558301C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
